Page 33 - NobleCon19revC2_Neat

AIM ImmunoTech Inc.

SELECTED FINANCIAL ITEMS AIM

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue 0.06 0.05 0.04 0.05 0.19
Gross Profit 0.06 0.05 0.04 0.02 0.16
Gross Margin 100% 100% 100% 35% 84%
EBIT (5.56) (4.30) (5.46) (8.16) (23.47)
EBIT Margin -9921% -8765% -13002% -17733% -12160%
Net Income to Common Shareholders (4.39) (3.66) (4.91) (7.82) (20.78)
Net Margin -7838% -7471% -11688% -16991% -10764%

Balance Sheet Key Items
Total Assets 40.49 37.46 33.62 27.86 27.86
Cash & Short Term Investments 27.05 23.40 21.04 15.26 15.26
% of Assets 67% 62% 63% 55% 55%
Current Assets -Total 36.32 33.16 28.87 22.74 22.74
% of Assets 90% 89% 86% 82% 82%
Total Liabilities 2.02 2.47 3.48 5.26 5.26
% of Assets 5% 7% 10% 19% 19%
Current Liabilities - Total 1.36 1.84 2.89 4.72 4.72
% of Assets 3% 5% 9% 17% 17%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 38.47 34.99 30.14 22.60 22.60
% of Assets 95% 93% 90% 81% 81%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (6.07) (3.68) (2.16) (5.67) (17.58)
Net Cash Flow - Investing 3.36 (0.08) (0.20) (0.34) 2.75
Net Cash Flow - Financing 0.00 0.10 0.01 0.23 0.34

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference